Chembio to Report COVID-19 Product Development Plans and Preliminary Estimated Second Quarter 2020 Revenue Results

NEXT STORY
Kessler Topaz Meltzer & Check, LLP – Important Deadline Reminder for Chembio Diagnostics, Inc. Investors
PREV STORY
FormFactor, Inc. Provides Updated Revenue Estimate for Second Quarter 2020
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Valeritas’ V-Go® Wearable Insulin Delivery Device Demonstrated Improved Clinical Benefits in Patients with Uncontrolled Type 2 Diabetes Previously Treated with Multiple Daily Injections

BRIDGEWATER, N.J., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a ...

author_avatar
NASDAQ Market News

New England Journal of Medicine publishes positive Phase 3 Dupixent® (dupilumab) results in children with moderate-to-severe asthma

author_avatar
NASDAQ Market News

UDPATE – Relay Medical and Fio Corporation Launch Mobile COVID-19 Testing and Tracking Platform

author_avatar
NASDAQ Market News